Loading…

Exploring a four-gene risk model based on doxorubicin resistance-associated lncRNAs in hepatocellular carcinoma

Liver cancer is a lethal cancer type among which hepatocellular carcinoma (HCC) is the most common manifestation globally. Drug resistance is a central problem impeding the efficiency of HCC treatment. Long non-coding RNAs reportedly result in drug resistance. This study aimed to identify key lncRNA...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2022-11, Vol.13, p.1015842
Main Authors: Zhang, Zunyi, Chen, Weixun, Luo, Chu, Zhang, Wei
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c419t-1b99b656f1a47937d4bae3e160844e7b47bfb95d228d2ade894082415b969cbb3
container_end_page
container_issue
container_start_page 1015842
container_title Frontiers in pharmacology
container_volume 13
creator Zhang, Zunyi
Chen, Weixun
Luo, Chu
Zhang, Wei
description Liver cancer is a lethal cancer type among which hepatocellular carcinoma (HCC) is the most common manifestation globally. Drug resistance is a central problem impeding the efficiency of HCC treatment. Long non-coding RNAs reportedly result in drug resistance. This study aimed to identify key lncRNAs associated with doxorubicin resistance and HCC prognosis. HCC samples with gene expression profiles and clinical data were accessed from public databases. We applied differential analysis to identify key lncRNAs that differed between HCC and normal samples and between drug-fast and control samples. We also used univariate Cox regression analysis to screen lncRNAs or genes associated with HCC prognosis. The least absolute shrinkage and selection operator (LASSO) was used to identify the key prognostic genes. Finally, we used receiver operating characteristic analysis to validate the effectiveness of the risk model. The results of this study revealed RNF157-AS1 as a key lncRNA associated with both doxorubicin resistance and HCC prognosis. Metabolic pathways such as fatty acid metabolism and oxidative phosphorylation were enriched in RNF157-AS1-related genes. LASSO identified four protein-coding genes- , , , and -to construct a risk model. The four-gene risk model effectively classified HCC samples into two risk groups with different overall survival. Finally, we established a nomogram, which showed superior performance in predicting the long-term prognosis of HCC. RNF157-AS1 may be involved in doxorubicin resistance and may serve as a potential therapeutic target. The four-gene risk model showed potential for the prediction of HCC prognosis.
doi_str_mv 10.3389/fphar.2022.1015842
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_95943c2af3a44237a19bf667699f6701</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_95943c2af3a44237a19bf667699f6701</doaj_id><sourcerecordid>2746391668</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-1b99b656f1a47937d4bae3e160844e7b47bfb95d228d2ade894082415b969cbb3</originalsourceid><addsrcrecordid>eNpVkUtv1DAURiMEolXpH2CBvGSTwa_4sUGqqtJWqkBCsLauH5lxSeJgJ6j8ezydoWq9sK_s7x5bPk3znuANY0p_6ucd5A3FlG4IJp3i9FVzSoRgrVaEvn5WnzTnpdzjOpjWTPC3zUmdOymxPG3S1cM8pBynLQLUpzW32zAFlGP5hcbkw4AslOBRmpBPDymvNro4oRxKLAtMLrRQSnIRlhoaJvf960VBNbALMyzJhWFYB8jIQa5taYR3zZsehhLOj-tZ8_PL1Y_Lm_bu2_Xt5cVd6zjRS0us1lZ0oifApWbScwuBBSKw4jxIy6Xtre48pcpT8EFpjhXlpLNaaGctO2tuD1yf4N7MOY6Q_5oE0TxupLw1kJfohmB0pzlzFHoGnFMmgWjbCyGF1r2QmFTW5wNrXu0YvAvTkmF4AX15MsWd2aY_RkusmOIV8PEIyOn3Gspixlj2fwNTSGsxVHLBdBWmapQeoi6nUnLon64h2OzFm0fxZi_eHMXXpg_PH_jU8l8z-wcnFKwp</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2746391668</pqid></control><display><type>article</type><title>Exploring a four-gene risk model based on doxorubicin resistance-associated lncRNAs in hepatocellular carcinoma</title><source>PubMed (Medline)</source><creator>Zhang, Zunyi ; Chen, Weixun ; Luo, Chu ; Zhang, Wei</creator><creatorcontrib>Zhang, Zunyi ; Chen, Weixun ; Luo, Chu ; Zhang, Wei</creatorcontrib><description>Liver cancer is a lethal cancer type among which hepatocellular carcinoma (HCC) is the most common manifestation globally. Drug resistance is a central problem impeding the efficiency of HCC treatment. Long non-coding RNAs reportedly result in drug resistance. This study aimed to identify key lncRNAs associated with doxorubicin resistance and HCC prognosis. HCC samples with gene expression profiles and clinical data were accessed from public databases. We applied differential analysis to identify key lncRNAs that differed between HCC and normal samples and between drug-fast and control samples. We also used univariate Cox regression analysis to screen lncRNAs or genes associated with HCC prognosis. The least absolute shrinkage and selection operator (LASSO) was used to identify the key prognostic genes. Finally, we used receiver operating characteristic analysis to validate the effectiveness of the risk model. The results of this study revealed RNF157-AS1 as a key lncRNA associated with both doxorubicin resistance and HCC prognosis. Metabolic pathways such as fatty acid metabolism and oxidative phosphorylation were enriched in RNF157-AS1-related genes. LASSO identified four protein-coding genes- , , , and -to construct a risk model. The four-gene risk model effectively classified HCC samples into two risk groups with different overall survival. Finally, we established a nomogram, which showed superior performance in predicting the long-term prognosis of HCC. RNF157-AS1 may be involved in doxorubicin resistance and may serve as a potential therapeutic target. The four-gene risk model showed potential for the prediction of HCC prognosis.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2022.1015842</identifier><identifier>PMID: 36457707</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>hepatocellular carcinoma ; lncRNAs ; long non-coding RNAs ; Pharmacology ; risk model ; RNF157-AS1</subject><ispartof>Frontiers in pharmacology, 2022-11, Vol.13, p.1015842</ispartof><rights>Copyright © 2022 Zhang, Chen, Luo and Zhang.</rights><rights>Copyright © 2022 Zhang, Chen, Luo and Zhang. 2022 Zhang, Chen, Luo and Zhang</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c419t-1b99b656f1a47937d4bae3e160844e7b47bfb95d228d2ade894082415b969cbb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708384/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708384/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36457707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Zunyi</creatorcontrib><creatorcontrib>Chen, Weixun</creatorcontrib><creatorcontrib>Luo, Chu</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><title>Exploring a four-gene risk model based on doxorubicin resistance-associated lncRNAs in hepatocellular carcinoma</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>Liver cancer is a lethal cancer type among which hepatocellular carcinoma (HCC) is the most common manifestation globally. Drug resistance is a central problem impeding the efficiency of HCC treatment. Long non-coding RNAs reportedly result in drug resistance. This study aimed to identify key lncRNAs associated with doxorubicin resistance and HCC prognosis. HCC samples with gene expression profiles and clinical data were accessed from public databases. We applied differential analysis to identify key lncRNAs that differed between HCC and normal samples and between drug-fast and control samples. We also used univariate Cox regression analysis to screen lncRNAs or genes associated with HCC prognosis. The least absolute shrinkage and selection operator (LASSO) was used to identify the key prognostic genes. Finally, we used receiver operating characteristic analysis to validate the effectiveness of the risk model. The results of this study revealed RNF157-AS1 as a key lncRNA associated with both doxorubicin resistance and HCC prognosis. Metabolic pathways such as fatty acid metabolism and oxidative phosphorylation were enriched in RNF157-AS1-related genes. LASSO identified four protein-coding genes- , , , and -to construct a risk model. The four-gene risk model effectively classified HCC samples into two risk groups with different overall survival. Finally, we established a nomogram, which showed superior performance in predicting the long-term prognosis of HCC. RNF157-AS1 may be involved in doxorubicin resistance and may serve as a potential therapeutic target. The four-gene risk model showed potential for the prediction of HCC prognosis.</description><subject>hepatocellular carcinoma</subject><subject>lncRNAs</subject><subject>long non-coding RNAs</subject><subject>Pharmacology</subject><subject>risk model</subject><subject>RNF157-AS1</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUtv1DAURiMEolXpH2CBvGSTwa_4sUGqqtJWqkBCsLauH5lxSeJgJ6j8ezydoWq9sK_s7x5bPk3znuANY0p_6ucd5A3FlG4IJp3i9FVzSoRgrVaEvn5WnzTnpdzjOpjWTPC3zUmdOymxPG3S1cM8pBynLQLUpzW32zAFlGP5hcbkw4AslOBRmpBPDymvNro4oRxKLAtMLrRQSnIRlhoaJvf960VBNbALMyzJhWFYB8jIQa5taYR3zZsehhLOj-tZ8_PL1Y_Lm_bu2_Xt5cVd6zjRS0us1lZ0oifApWbScwuBBSKw4jxIy6Xtre48pcpT8EFpjhXlpLNaaGctO2tuD1yf4N7MOY6Q_5oE0TxupLw1kJfohmB0pzlzFHoGnFMmgWjbCyGF1r2QmFTW5wNrXu0YvAvTkmF4AX15MsWd2aY_RkusmOIV8PEIyOn3Gspixlj2fwNTSGsxVHLBdBWmapQeoi6nUnLon64h2OzFm0fxZi_eHMXXpg_PH_jU8l8z-wcnFKwp</recordid><startdate>20221110</startdate><enddate>20221110</enddate><creator>Zhang, Zunyi</creator><creator>Chen, Weixun</creator><creator>Luo, Chu</creator><creator>Zhang, Wei</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20221110</creationdate><title>Exploring a four-gene risk model based on doxorubicin resistance-associated lncRNAs in hepatocellular carcinoma</title><author>Zhang, Zunyi ; Chen, Weixun ; Luo, Chu ; Zhang, Wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-1b99b656f1a47937d4bae3e160844e7b47bfb95d228d2ade894082415b969cbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>hepatocellular carcinoma</topic><topic>lncRNAs</topic><topic>long non-coding RNAs</topic><topic>Pharmacology</topic><topic>risk model</topic><topic>RNF157-AS1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Zunyi</creatorcontrib><creatorcontrib>Chen, Weixun</creatorcontrib><creatorcontrib>Luo, Chu</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Zunyi</au><au>Chen, Weixun</au><au>Luo, Chu</au><au>Zhang, Wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exploring a four-gene risk model based on doxorubicin resistance-associated lncRNAs in hepatocellular carcinoma</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2022-11-10</date><risdate>2022</risdate><volume>13</volume><spage>1015842</spage><pages>1015842-</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Liver cancer is a lethal cancer type among which hepatocellular carcinoma (HCC) is the most common manifestation globally. Drug resistance is a central problem impeding the efficiency of HCC treatment. Long non-coding RNAs reportedly result in drug resistance. This study aimed to identify key lncRNAs associated with doxorubicin resistance and HCC prognosis. HCC samples with gene expression profiles and clinical data were accessed from public databases. We applied differential analysis to identify key lncRNAs that differed between HCC and normal samples and between drug-fast and control samples. We also used univariate Cox regression analysis to screen lncRNAs or genes associated with HCC prognosis. The least absolute shrinkage and selection operator (LASSO) was used to identify the key prognostic genes. Finally, we used receiver operating characteristic analysis to validate the effectiveness of the risk model. The results of this study revealed RNF157-AS1 as a key lncRNA associated with both doxorubicin resistance and HCC prognosis. Metabolic pathways such as fatty acid metabolism and oxidative phosphorylation were enriched in RNF157-AS1-related genes. LASSO identified four protein-coding genes- , , , and -to construct a risk model. The four-gene risk model effectively classified HCC samples into two risk groups with different overall survival. Finally, we established a nomogram, which showed superior performance in predicting the long-term prognosis of HCC. RNF157-AS1 may be involved in doxorubicin resistance and may serve as a potential therapeutic target. The four-gene risk model showed potential for the prediction of HCC prognosis.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>36457707</pmid><doi>10.3389/fphar.2022.1015842</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2022-11, Vol.13, p.1015842
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_95943c2af3a44237a19bf667699f6701
source PubMed (Medline)
subjects hepatocellular carcinoma
lncRNAs
long non-coding RNAs
Pharmacology
risk model
RNF157-AS1
title Exploring a four-gene risk model based on doxorubicin resistance-associated lncRNAs in hepatocellular carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T11%3A25%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exploring%20a%20four-gene%20risk%20model%20based%20on%20doxorubicin%20resistance-associated%20lncRNAs%20in%20hepatocellular%20carcinoma&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Zhang,%20Zunyi&rft.date=2022-11-10&rft.volume=13&rft.spage=1015842&rft.pages=1015842-&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2022.1015842&rft_dat=%3Cproquest_doaj_%3E2746391668%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c419t-1b99b656f1a47937d4bae3e160844e7b47bfb95d228d2ade894082415b969cbb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2746391668&rft_id=info:pmid/36457707&rfr_iscdi=true